Oxford Nanopore Technologies has secured a GBP 50 million (~USD 63.6 million) investment from Novo Holdings as a part of an equity issue, with plans to make future investments with further purchases in the secondary market, subject to availability and price.
Oxford Nanopore plans to use Novo Holdings' knowledge of the biopharmaceutical market to leverage its technology to meet the needs of this industry. The main focus will be on information-rich, rapid, and simplified sequencing to develop and deliver biopharmaceuticals quickly with less complexity.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.